Article Contents ::
- 1 The Brand Name PLANEP Has Generic Salt :: EPLERENONE
- 2 PLANEP Is From Company Lupin Priced :: Rs. 250
- 3 PLANEP have EPLERENONE is comes under Sub class Anti Hypertensives of Main Class Cardiovascular System
- 4 Main Medicine Class:: Cardiovascular System Sub Medicine Class :: Anti Hypertensives
- 5 Disclaimer ::
- 6 The Information available on this site is for only Informational Purpose , before any use of this information please consult your Doctor .Price of the drugs indicated above may not match to real price due to many possible reasons may , including local taxes etc.. These are only approximate indicative prices of the drug.
The Brand Name PLANEP Has Generic Salt :: EPLERENONE
PLANEP Is From Company Lupin Priced :: Rs. 250
PLANEP have EPLERENONE is comes under Sub class Anti Hypertensives of Main Class Cardiovascular System
Main Medicine Class:: Cardiovascular System Sub Medicine Class :: Anti Hypertensives
|Salt Name : OR Generic Name||Form||Price : MRP /Probable||Packing|
Indications for Drugs ::
Hypertension, Heart failure, Congestive heart failure, Left ventricular dysfunction, Acute myocardial infarction
Drug Dose ::
Adult: PO CHF Post-MI Initial: 25 mg once daily; titrate to recommended dose of 50 mg once daily w/in 4 wk as tolerated. Adjust dose based on serum potassium level; reduce or w/draw therapy if hyperkalaemia develops. HTN Initial: 50 mg once daily; may increase to 50 mg twice daily based on response. Initiate at lower dose of 25 mg once daily if used concurrently w/ moderate CYP3A4 inhibitors.
For all patients: Serum potassium >5.5 mEq/L at initiation; CrCl ?30 mL/min; concomitant use of strong CYP3A4 inhibitors (e.g. ketoconazole, itraconazole, nefazodone, troleandomycin, clarithromycin, ritonavir, nelfinavir). For patients treated for hypertension: Patients with type 2 DM with microalbuminuria; serum creatinine >2 mg/dL (male), or >1.8 mg/dL (female); CrCl <50 mL/min; concomitant use of potassium supplements or potassium-sparing diuretics (e.g. amiloride, spironolactone, or triamterene). Drug Precautions ::
Measure serum potassium levels before starting therapy, within the first wk, and periodically thereafter. Increased risk of hyperkalaemia in patients with impaired renal functions; diabetic patients with CHF post-MI (especially those with proteinuria); or concurrent use of agents affecting the rennin-angiotensin-aldosterone system. Safety and efficacy not established in patients with severe hepatic impairment; or paediatric patients <18 yr. Elderly. Pregnancy and lactation. Drug Side Effects ::
Hyperkalaemia, hyponatraemia, dizziness, headache, abdominal pain, diarrhoea, cough, fatigue, influenza-like symptoms, abnormal vaginal bleeding, gynaecomastia, mastodynia, myocardial infarction, angina pectoris, hypercholesterolaemia, hypertriglyceridaemia, albuminuria, increased creatinine, elevated liver enzymes, increased uric acid, rash and angioneurotic oedema.
Pregnancy category ::
Drug Mode of Action ::
Aldosterone binds to mineralocorticoid receptors in both epithelial (e.g. kidney, GI tract) and nonepithelial (e.g. heart, blood vessels, brain) tissues; causing increases in blood pressure by inducing sodium reabsorption, vascular remodeling, water retention and possibly other mechanisms. Eplerenone is a relatively selective mineralocorticoid receptor antagonist, blocking binding of aldosterone and reducing blood pressure. Eplerenone also appears to have cardioprotective effect in patients with congestive heart failure (CHF) after myocardial infarction (MI).
Drug Interactions ::
Concomitant use with CYP3A4 Inhibitors (e.g. ketoconazole, voriconazole, itraconazole, fluconazole, clarithromycin, diltiazem saquinavir, verpamil, ritonavir) may increase serum concentrations of Eplerenone. CYP3A4 inducers (e.g. rifampicin, carbamazepine, phenytoin, phenobarbital) may decrease Eplerenone efficacy. Eplerenone may enhance hyperkalaemic effect of ACE inhibitors, angiotensin II receptor blockers, potassium-sparing diuretics or potassium salts. Concomitant use with diazoxide, MAOIs, pentoxifylline, prostacyclin analogues may enhance hypotensive effect of antihypertensives. NSAIDs may possibly reduce the antihypertensive and/or diuretic effects of potassium-sparing diuretics and may increase risk of hyperkalaemia. Lithium toxicity has been reported when used with ACE inhibitors or diuretics; monitor lithium levels when used with Eplerenone.